Table 2.
Clinical characteristics of the patients according to VAFmean at baseline and VAFmean-change
| VAFmean at baseline | VAFmean-change | |||||
|---|---|---|---|---|---|---|
| high (≥0.85%a) | low (< 0.85%a) | p | < 0 | ≥0 | p | |
| sex (female/male) | 2/10 | 4/8 | 0.6404 | 5/12 | 1/5 | 1 |
| age, median | 74 (67–84) | 71.5 (54–88) | 0.5826 | 71 (58–84) | 76 (68–88) | 0.1825 |
| ALBI Grade, G1/G2, n | 5/7 | 4/8 | 1 | 6/11 | 3/3 | 0.643 |
| TNM, n | ||||||
| 4b/other | 7/5 | 6/6 | 1 | 10/7 | 3/3 | 1 |
| 4/other | 9/3 | 8/4 | 1 | 13/4 | 3/3 | 0.3185 |
| T, n | ||||||
| 3 or 4/0–2 | 8/4 | 6/6 | 0.6802 | 10/7 | 4/2 | 1 |
| 4/0–3 | 1/11 | 2/10 | 1 | 2/15 | 1/5 | 1 |
| M, 1/0, n | 7/5 | 5/7 | 0.6843 | 9/8 | 3/3 | 1 |
| N, 1/0, n | 3/9 | 4/8 | 1 | 5/12 | 1/5 | 1 |
| BCLC, B/C, n | 3/9 | 4/8 | 1 | 4/13 | 3/3 | 0.3185 |
| AFP,median, ng/mL | 5.05 (0.5–1085.9) | 193 (0.5–14,240) | 0.0463 | 29 (0.5–142,400) | 8.1 (0.5–1998.6) | 0.441 |
| DCP, median, mAU/mL | 133.5 (13–37,535) | 682 (14–16,575) | 0.6033 | 143 (13–16,575) | 1270.5 (27–37,535) | 0.3627 |
| MVI, presence/absence, n | 1/11 | 1/11 | 1 | 2/15 | 0/6 | 1 |
| History of prior treatment (yes/no), n | ||||||
| Systemic therapy | 3/9 | 3/9 | 1 | 4/13 | 2/4 | 0.6322 |
| Catheter treatment | 8/4 | 10/2 | 0.6404 | 13/4 | 4/2 | 0.6322 |
| Local therapy | 9/3 | 8/4 | 1 | 12/5 | 4/2 | 1 |
| Radiation therapy | 2/10 | 3/9 | 1 | 5/12 | 0/6 | 0.2725 |
VAF variant allele frequency, ALBI Albumin-bilirubin, TNM Tumor, Node, Metastasis, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, DCP des-gamma-carboxy pro- thrombin, MVI macroscopic portal vein invasion
aThe cut-off value of VAFmean at baseline set to median